Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2

Shares :

  • IND filing today for STI-1499 (COVI-GUARD™) for hospitalized COVID-19 patients.
  • The initial trial is expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization) as early as the end of this year.
  • Animal model data (Syrian Golden Hamsters infected with SARS-CoV-2) confirm the neutralizing profile and high potency of this antibody, expected effective dose in human to be at least 5 times lower than current known antibodies being assessed in other active trials.
  • Additional in-vitro experiments demonstrated the complete virus neutralizing property of STI-1499 against the highly contagious D614G SARS-CoV-2 variant.
  • Sorrento has initiated cGMP manufacturing to produce 50,000 doses, expected to be available by the end of this year, in anticipation of a potential EUA.

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced that it is filing an investigational new drug application (IND) for COVI-GUARD (STI-1499) for hospitalized COVID-19 patients today.

Sorrento has previously received guidance from the FDA in response to a pre-IND meeting package and believes it has addressed all questions and followed the recommendations from the agency for all sections of the IND.

As Sorrento previously announced, in preclinical studies, STI-1499 demonstrated 100% neutralizing effect (in vitro) of the antibody and that a low dose prevented SARS-CoV-2 from infecting healthy cells in such preclinical in vitro studies.

Animal data generated by Dr. Paessler’s laboratory at the University of Texas Medical Branch at Galveston (UTMB) in Syrian Golden Hamsters infected with SARS-CoV-2, justify the IND filing and continued clinical development. This established model, while limited, is the most predictive animal model currently available for this disease. The data were presented to federal agencies and will be published as soon as possible in a scientific journal.

The highest proposed dose (200 mg per patient) in the phase 1 safety trial is a much lower dose than currently being tested for other known antibodies in active clinical studies. The potentially higher potency of the antibody may allow for faster scaled manufacturing (availability to patients) and potentially a lower cost per dose as compared to other known antibodies currently being evaluated.

STI-1499 antibody has also been evaluated in preclinical studies against multiple strains of SARS-CoV-2, including the highly contagious D614G mutant, the current dominant strain globally. In such preclinical studies, the antibody has been 100% effective against the highly contagious D614G mutant strain at a low dose.

More information about the phase 1 clinical trial can be found on www.clinicaltrials.gov (NCT# 04454398).

About Sorrento Therapeutics, Inc.  
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™ and T-VIVA-19™; and diagnostic test solutions, including COVI-TRACK™ and COVI-TRACE™. Sorrento’s commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.  ZTlido® was approved by the FDA on February 28, 2018.

For more information, visit www.sorrentotherapeutics.com

M2Bio Sciences inc, an opportunity of a lifetime?| LOOK HERE

Sign up for MORE news updates


This article is written and published by The Stocks market 


Disclaimer : The Stocks market does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Stocks market are engaged in the business of marketing and advertising companies.

The Stocks market and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.


Shares :